The Life Sciences team represented Nimbus Therapeutics in the completion of its first closing of approximately $65 million Series 2018 preferred stock financing. The new capital will help accelerate the company’s pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease. The investment round was led by Atlas and Lilly Ventures.
Goodwin has worked with Nimbus since its formation and initial funding in 2009. The team has advised on the company’s $43 million Series B financing round, the $1.2 billion sale of Nimbus Apollo (Nimbus’s clinical stage ACC program) to Gilead Sciences, and a long-term strategic alliance with Celgene Corporation to develop treatments for autoimmune disorders.
Nimbus Therapeutics is a biotechnology company pioneering the application of highly advanced computational technologies to the design and development of novel treatments for substantial and underserved human diseases.
The Goodwin team was led by partners Mitchell Bloom and William Collins and included partner Daniel Karelitz and associates Gabriela Morales-Rivera, Sarah Smith and Kyle Pine.
For additional details on the financing, please read the press release.